Still several unknowns here: 1. Unsecured Creditors trying to delay sale until FDA approval for Virtis. 2. Unsecured Creditors trying to disgorge $35M payment to Secured Creditors as a fraudulent conveyance. 3. Excluded assets from IP sale that could bring value (Real Property/Equipment and Aleva license). Any or all of these things could result in positive value for equity.